The Major Global Expansion of Rx-to-OTC Switch by 2016
BEDMINSTER, NJ, Sep 18, 2013 (Marketwired via COMTEX) --
Elsevier Business Intelligence, publisher of "The Tan Sheet" and
"The Pink Sheet," announced collaboration with Francesco
International to distribute a new report: "The Major Global Expansion
of Rx-to-OTC Switch by 2016."
"Rx-to-OTC switch is changing dramatically" according to Steven
Francesco, CEO of consultancy, Francesco International. The report
covers the emergence of new technology, combined with new legislative
action and a more proactive regulatory environment. By 2016 "switch"
has the potential to have a multi-billion dollar impact on global
healthcare outcomes and costs, especially in the cardiovascular,
respiratory and central nervous system areas. Switching the $4
billion Lipitor is just one example. Understanding and managing these
new business drivers is key.
This report focuses on providing serious strategic and operational
-- Companies interested in understanding the importance and potential of
business opportunities of these technologically Enhanced OTC
-- Companies who will experience the impact by a competitor of achieving
an Enhanced OTC (OTC-E(TM)) Drugs Rx-to-OTC switch and lowering
To view the table of contents please visit: Rx-to-OTC Switch Forecast
Mr. Francesco states that "We are delighted to partner for the first
time with global publisher Elsevier on this important subject. The
world of Rx-to-OTC switch will become significantly more active as
many new and diverse technology tools will enhance the safe use of
numerous prescription drugs in an OTC setting. Moreover, the new
openness of the regulators to this new set of healthcare
opportunities that will drive down costs should be on the radar
screens of all those active in our evolving healthcare industry. The
potential financial impact on the US prescription business alone
could be in excess of $18 billion in sales by 2016."
"At Elsevier Business Intelligence, we are committed to delivering
world-class business intelligence on regulatory, business and
reimbursement issues that are vital to the healthcare industry," said
Deanna Flanick, Vice President, Sales & Marketing, Elsevier Business
Intelligence. "Our strategic distribution agreement with Francesco
International is a great step in providing top class Rx-to-OTC switch
guidance to CEOs, Business Development Leaders, Rx & OTC teams
Purchase your copy of "The Major Global Expansion of Rx-to-OTC Switch
Francesco International (www.franint.com) has been involved in
lifecycle management and especially Rx-to-OTC switch for 19 years.
Francesco International published the newsletter, SWITCH, for 9 years
as well as SWITCH Market Impact and Dual Status studies. Francesco
International is also known for its "Max the Molecule" software that
combines qualitative and quantitative factors which ultimately
generates customized financially sensitive scenarios that maximize
late stage product lifecycle strategies.
About Elsevier Business Intelligence
Elsevier Business Intelligence
(EBI), an Elsevier company built on the heritage of F-D-C Reports,
Windhover Information and Medtech Insight, is a global information
supplier providing business intelligence on regulatory, business and
reimbursement issues that are vital to the healthcare industry.
Through a range of products including publications, conferences,
databases and reports, EBI places biopharma and medical device
professionals, and those who focus on these industries, at the
forefront of knowledge, by providing the perfect combination of news
and information together with penetrating insight and analysis. EBI
(www.elsevierbi.com) has offices in the U.S. in Bedminster, N.J.;
Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.
Elsevier Business Intelligence
+1 908 748 1185
+1 973 985 0589 (c)
SOURCE: Elsevier Business Intelligence
[ Back To Technology News's Homepage ]